|
|
Article: Eyetech Signs Aptamer Leader Archemix To Ophthalmic Deal.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
National Editor
You might have seen it coming.
Eyetech Pharmaceuticals Inc.'s deal with Archemix Corp. for aptamers targeting ophthalmic indications teams two firms that, years ago, each took some of the Selex technology offered by Gilead Sciences Inc.
New York-based Eyetech licensed the aptamer Macugen (pegaptanib sodium) in April 2000, and since has turned the drug into a potential blockbuster for age-related macular degeneration. The company expects to file a new drug application in the third quarter.
"In 2001, we got everything else [of Selex]," said Errol De Souza, president and CEO of Cambridge, Mass.-based Archemix, noting that ...
Related newspaper, magazine, and journal articles:
|
|
Article: COMPANY FORGING AHEAD WITH DIABETES DRUG AMYLIN STOCK DROPS 77 ...
BIOWORLD Today;
October 22, 1998 ;
700+ words
... ... price dropped below $8.50. (See BioWorld Today, Aug. 19, 1997, p. 1.) Along ... U.S. and Europe," Krawiec told BioWorld Today. Tanner said Amylin's move to continue ... J $36 million from a loan. (See BioWorld Today, March 3, 1998, p. 1.) Terms ...
|
|